Gene expression signature-defined necroinflammation is not associated with sex-biased survival or bevacizumab benefit in glioblastoma
Neuro Oncol
.
2024 Nov 15:noae216.
doi: 10.1093/neuonc/noae216.
Online ahead of print.
Authors
Johannes Weller
1
2
3
,
Emre Kocakavuk
4
,
Barbara Pregler
5
,
Thomas Zeyen
2
3
,
Niklas Schäfer
2
3
,
Anna-Laura Potthoff
5
,
Matthias Schneider
5
,
Ulrich Herrlinger
2
3
Affiliations
1
Department of Vascular Neurology, Center of Neurology, University Hospital Bonn, Bonn, Germany.
2
Center of Integrated Oncology (CIO ABCD), University Hospital Bonn, Bonn, Germany.
3
Department of Neurooncology, Center of Neurology, University Hospital Bonn, Bonn, Germany.
4
Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany.
5
Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.
PMID:
39545540
DOI:
10.1093/neuonc/noae216
No abstract available
Keywords:
bevacizumab; glioblastoma; necroinflammation; newly diagnosed glioblastoma.